ResMed (NYSE: RMD) reported Q4 EPS of $1.49, $0.04 better than the analyst estimate of $1.45. Revenue for the quarter came in at $914.7 million versus the consensus estimate of $910.54 million.

For earnings history and earnings-related data on ResMed (RMD) click here.